Dabigatran: An Oral Direct Thrombin Inhibitor

February 2010
Travel Medicine Advisor;Feb2010 Supplement, p1
The article focuses on the study concerning the use of dabigatran in treating patients with acute venous thromboembolism. It says that dabigatran is an oral direct thrombin inhibitor which is used by many countries as an alternative to warfarin. Moreover, the drug has shown to be as effective as warfarin in preventing stoke in patients with atrial fibrillation in which it does not require monitoring with blood tests.


Related Articles

  • Dabigatran: An Oral Direct Thrombin Inhibitor. Elliott, William T. // Clinical Oncology Alert;Feb2010 Supplement 2, p1 

    The article discusses results from a Phase 3 study of the oral direct thrombin inhibitor dabigatran. This drug is being used as an alternative to warfarin, but does not require monitoring with blood tests. Warfarin is effective in the prevention of stroke in patients with atrial fibrillation....

  • The Current and Future Role of the Novel Oral Anticoagulants—Indications Beyond Atrial Fibrillation. Lee, Adam; Rajaratnam, Rohan // Heart, Lung & Circulation;Jan2014, Vol. 23 Issue 1, p2 

    Abstract: The direct thrombin inhibitors and Factor-Xa inhibitors are novel oral anticoagulants which are gaining rapid acceptance not only as alternatives to warfarin, but also as recommended first line agents for use as stroke prophylaxis in patients with non-valvular atrial fibrillation....

  • In AF requiring warfarin interruption, no anticoagulation bridging was noninferior to bridging for thromboembolism. Donato, Anthony // Annals of Internal Medicine;11/17/2015, Vol. 163 Issue 10, pJC5 

    The article presents questions and answers related to atrial fibrillation (AF) including no bridging noninferior to bridging with low-molecular-weight heparin (LMWH)for perioperative arterial thromboembolism (ATE) in patients with AF, and whether it reduces major bleeding.

  • Bleeds discourage use of warfarin.  // Pulse;1/19/2006, Vol. 66 Issue 3, p18 

    The article reports on a study showing that physicians prescribe warfarin less often after having a stroke patient who has suffered an anticoagulation-related bleed. The research was led by Niteesh Choudhry, instructor in medicine at Harvard Medical School. The research team warned that as the...

  • Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations. Saraf, Karan; Morris, Paul; Garg, Pankaj; Sheridan, Paul; Storey, Robert // Postgraduate Medical Journal;Sep2014, Vol. 90 Issue 1067, p520 

    Warfarin, a vitamin K antagonist, is the most widely used oral anticoagulant in the world. It is cheap and effective, but its use is limited in many patients by unpredictable levels of anticoagulation, which increases the risk of thromboembolic or haemorrhagic complications. It also requires...

  • Will this be the End of the Anticoagulation Clinic for Patients with Atrial Fibrillation? Mitchell, Andrew R.J. // Current Drug Targets - Cardiovascular & Haematological Disorders;Oct2005, Vol. 5 Issue 5, p405 

    Atrial fibrillation is the most common clinical arrhythmia and with an ageing population, it is an increasing cause of hospital admissions, morbidity and mortality. The most feared complication of atrial fibrillation is stroke. A number of studies have demonstrated that warfarin is at least...

  • Predictors of Thromboembolism in Atrial Fibrillation: I. Clinical Features of Patients at Risk. Anderson, David C.; Asinger, Richard W.; Newburg, Susan M.; Hayward, Arthur; MacMillan, Kate; Kanter, Merrill C.; Logan, William R.; Hamilton, William P.; Bacon, Rebecca S.; Redd, Robert M.; Labovitz, Arthur J.; Kelley, Roger E.; Feinberg, William M.; Vold, Brenda K.; Kern, Karl B.; Cohen, Bruce A.; Martin, Gary J.; Weinberger, Jesse M.; Goldman, Martin E. // Annals of Internal Medicine;1/1/92, Vol. 116 Issue 1, p1 

    Identifies the predictors of thromboembilism in atrial fibrillation. Efficacy of warfarin for antithrombotic therapy; Analysis on several features of thromboembolism; Variables that predicted a risk for thromboembolism.

  • Warfarin use affected by physician exposure to adverse events.  // Reactions Weekly;2/18/2006, Issue 1089, p5 

    Discusses research being done on the impact of adverse events on prescribing warfarin in patients with atrial fibrillation, reference to a study by N. K. Choudhry and colleagues, published in the January 21, 2006 issue of the "British Medical Journal." Number of physicians who care for patients...

  • Stroke in AF. Nichols, Emma Hitt; Lip, Gregory Y. H.; Camm, A. John; Whitlock, Richard // MD Conference Express;Jun2015, Vol. 15 Issue 12, p15 

    Patients with atrial fibrillation are at increased risk of stroke, and the addition of a single risk factor indicates a need for prophylaxis with warfarin or a non-VKA oral anticoagulant. Left atrial appendage occlusion is a potential alternative if long-term anticoagulation is contraindicated.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics